Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals Inc. are doing their best to keep their late-stage prostate cancer drug competitive, despite the positive announcements from other entrants coming to the market. As a means of carving out a niche for custirsen, the two companies have altered their Phase III program.
OncoGenex announced March 8, along with its fourth quarter earnings, that its plans with Teva for the development of custirsen,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?